Finance

Smallpox vaccine maker gives clinical update, reports DKK 414.3M in revenue

Published in Vaccine Weekly, November 26th, 2003

For the period January 1 through September 30, 2003, Bavarian Nordic generated a revenue of DKK 414.3 million and a profit before interest and tax (EBIT) of DKK 192.7 million.

Operating income in the first 9 months of 2003 was earned from ongoing smallpox vaccine contracts with the governments of the U.K., Germany, and the U.S. This trend is expected to continue in the fourth quarter. Third-quarter revenue was DKK 232.8 million and a profit before interest and tax of DKK 133.0 million.

In the extended phase I/II study to monitor HIV levels in immune-compromised individuals who had previously received three MVA-BN nef vaccinations, five patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-11-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry